Study Reveals the Effect of Sodium Glucose and Glucose Inhibitors on Type 2 Diabetes Patients

AstraZeneca, based in Dubai, revealed the results of its experience on the relationship between cardiovascular disease and type 2 diabetes. This is the largest study of SGLT2 inhibitors to date.

The DECLARE study was successful in achieving its initial goals in terms of confirming the initial safety of the various symptoms associated with cardiovascular disease in patients who underwent this test. Heart failure is one of the first and most common cardiovascular diseases in patients with type 2 diabetes. Many sudden deaths in diabetic patients are associated with dysfunction and ventricular dysfunction compared with heart failure. to a myocardial infarction.

The results of the DECLARE-TIMI 58 trial provide compelling evidence that antidiabetic drugs containing these inhibitors help meet the basic medical needs of a diverse group of patients with type 2 diabetes. The study involved more than 17,000 patients in 33 countries and showed a significant reduction in hospitalization needs for heart failure or cardiovascular disease deaths up to 17% compared to other treatments.

The experience gained with DECLARE-TIMI 58 also confirmed the safety of this type of pharmacokinetics, which responded to the main safety indicators developed with placebo, indicating that there was no increase in MACE, defined as a death from heart disease. Blood vessel or heart attack (myocardial infarction) or stroke.

With respect to the other relevant safety measures, the experiment showed no problem of ingestion of drugs containing SGLT2 inhibitors compared to placebo during amputations (1, 4% vs. 1.3%) and fractures (5.3% vs. 5%). 1%), bladder cancer (0.3% vs. 0.5%) or upper gangrene (one in five cases). Cases of diabetic ketoacidosis (0.3% vs. 0.1%) and genital infections (0.9% vs. 0.1%) were rare.

The results of this unique trial are particularly important because heart failure is one of the early and recurrent complications of diabetes, resulting in a significant social and economic burden. SGLT2 inhibitors can play a vital role in improving patient care, and recent scientific studies have shown the positive effects of these inhibitors on the heart and blood vessels.